BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8638362)

  • 1. Reference range of prostate-specific antigen after transurethral resection of the prostate.
    Aus G; Bergdahl S; Frösing R; Lodding P; Pileblad E; Hugosson J
    Urology; 1996 Apr; 47(4):529-31. PubMed ID: 8638362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered prostate specific antigen reference range after transurethral resection of the prostate.
    Wolff JM; Boekels O; Borchers H; Jakse G; Rohde D
    Anticancer Res; 2000; 20(6D):4977-80. PubMed ID: 11326651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia.
    Marks LS; Dorey FJ; Rhodes T; Shery ED; Rittenhouse H; Partin AW; deKernion JB
    J Urol; 1996 Sep; 156(3):1035-9. PubMed ID: 8709302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in serum prostate-specific antigen level after prostatectomy in patients with benign prostatic hyperplasia.
    Hosseini SY; Salimi M; Hosseini Moghaddam SM
    Urol J; 2005; 2(4):183-8. PubMed ID: 17602426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of transurethral resection of the prostate in "asymptomatic" patients with an elevated prostate-specific antigen level.
    van Renterghem K; Van Koeveringe G; Achten R; Van Kerrebroeck P
    Eur Urol; 2007 Sep; 52(3):819-26. PubMed ID: 17418482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
    Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
    BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of free to total prostate specific antigen ratio in serum in the diagnosis of prostatic enlargement.
    Bhuiyan AK; Kibria SA; Subhan SS
    Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):51-9. PubMed ID: 15813483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of transurethral indwelling catheter on serum prostate-specific antigen level in benign prostatic hyperplasia.
    Batislam E; Arik AI; Karakoc A; Uygur MC; Germiyanoğlu RC; Erol D
    Urology; 1997 Jan; 49(1):50-4. PubMed ID: 9000185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
    Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
    Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer].
    Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
    Hinyokika Kiyo; 1998 Sep; 44(9):639-43. PubMed ID: 9805668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia.
    España F; Martínez M; Royo M; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF
    Eur Urol; 1997; 32(3):268-72. PubMed ID: 9358211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prostate cancer after prostatectomy for benign prostatic hyperplasia].
    Hua L; Zhang J; Wu H; Sui Y; Zhang W; Qian L; Wang Z
    Zhonghua Nan Ke Xue; 2004 Aug; 10(8):612-3. PubMed ID: 15362527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g.
    Gupta N; Sivaramakrishna ; Kumar R; Dogra PN; Seth A
    BJU Int; 2006 Jan; 97(1):85-9. PubMed ID: 16336334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
    Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
    Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.